These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 27491296)

  • 1. BET bromodomain proteins and epigenetic regulation of inflammation: implications for type 2 diabetes and breast cancer.
    Nicholas DA; Andrieu G; Strissel KJ; Nikolajczyk BS; Denis GV
    Cell Mol Life Sci; 2017 Jan; 74(2):231-243. PubMed ID: 27491296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BET Bromodomain as a Target of Epigenetic Therapy.
    Noguchi-Yachide T
    Chem Pharm Bull (Tokyo); 2016; 64(6):540-7. PubMed ID: 27250788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic BET reader inhibitor apabetalone (RVX-208) counters proinflammatory aortic gene expression in a diet induced obesity mouse model and in human endothelial cells.
    Wasiak S; Tsujikawa LM; Daze E; Gilham D; Stotz SC; Rakai BD; Sarsons CD; Fu L; Azhar S; Jahagirdar R; Sweeney M; Johansson JO; Wong NCW; Kulikowski E
    Atherosclerosis; 2023 Jan; 364():10-19. PubMed ID: 36455344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BET domain co-regulators in obesity, inflammation and cancer.
    Belkina AC; Denis GV
    Nat Rev Cancer; 2012 Jun; 12(7):465-77. PubMed ID: 22722403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenetic Reprogramming of the Inflammatory Response in Obesity and Type 2 Diabetes.
    Zatterale F; Raciti GA; Prevenzano I; Leone A; Campitelli M; De Rosa V; Beguinot F; Parrillo L
    Biomolecules; 2022 Jul; 12(7):. PubMed ID: 35883538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Bromodomain and Extra-Terminal Domain (BET) Family: Functional Anatomy of BET Paralogous Proteins.
    Taniguchi Y
    Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27827996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bromodomain and extra-terminal (BET) family proteins: New therapeutic targets in major diseases.
    Padmanabhan B; Mathur S; Manjula R; Tripathi S
    J Biosci; 2016 Jun; 41(2):295-311. PubMed ID: 27240990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the epigenetic reader "BET" as a therapeutic strategy for cancer.
    Wahi A; Manchanda N; Jain P; Jadhav HR
    Bioorg Chem; 2023 Nov; 140():106833. PubMed ID: 37683545
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Nord JA; Wynia-Smith SL; Gehant AL; Jones Lipinski RA; Naatz A; Rioja I; Prinjha RK; Corbett JA; Smith BC
    Front Endocrinol (Lausanne); 2022; 13():923925. PubMed ID: 36176467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigenetic blockade of neoplastic transformation by bromodomain and extra-terminal (BET) domain protein inhibitor JQ-1.
    Zhang C; Su ZY; Wang L; Shu L; Yang Y; Guo Y; Pung D; Bountra C; Kong AN
    Biochem Pharmacol; 2016 Oct; 117():35-45. PubMed ID: 27520485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bromodomain inhibitors and cancer therapy: From structures to applications.
    Pérez-Salvia M; Esteller M
    Epigenetics; 2017 May; 12(5):323-339. PubMed ID: 27911230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The inflammatory effect of epigenetic factors and modifications in type 2 diabetes.
    Akbari M; Hassan-Zadeh V
    Inflammopharmacology; 2020 Apr; 28(2):345-362. PubMed ID: 31707555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BET Bromodomain Proteins as Cancer Therapeutic Targets.
    Shu S; Polyak K
    Cold Spring Harb Symp Quant Biol; 2016; 81():123-129. PubMed ID: 28062533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemical modulators for epigenome reader domains as emerging epigenetic therapies for cancer and inflammation.
    Zaware N; Zhou MM
    Curr Opin Chem Biol; 2017 Aug; 39():116-125. PubMed ID: 28689146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bromodomain coactivators in cancer, obesity, type 2 diabetes, and inflammation.
    Denis GV
    Discov Med; 2010 Dec; 10(55):489-99. PubMed ID: 21189220
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging roles of and therapeutic strategies targeting BRD4 in cancer.
    White ME; Fenger JM; Carson WE
    Cell Immunol; 2019 Mar; 337():48-53. PubMed ID: 30832981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenetic processing in cardiometabolic disease.
    Costantino S; Mohammed SA; Ambrosini S; Paneni F
    Atherosclerosis; 2019 Feb; 281():150-158. PubMed ID: 30290963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetic targeting of Hedgehog pathway transcriptional output through BET bromodomain inhibition.
    Tang Y; Gholamin S; Schubert S; Willardson MI; Lee A; Bandopadhayay P; Bergthold G; Masoud S; Nguyen B; Vue N; Balansay B; Yu F; Oh S; Woo P; Chen S; Ponnuswami A; Monje M; Atwood SX; Whitson RJ; Mitra S; Cheshier SH; Qi J; Beroukhim R; Tang JY; Wechsler-Reya R; Oro AE; Link BA; Bradner JE; Cho YJ
    Nat Med; 2014 Jul; 20(7):732-40. PubMed ID: 24973920
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bromodomain and extraterminal domain-containing protein inhibition attenuates acute inflammation after spinal cord injury.
    Rudman MD; Choi JS; Lee HE; Tan SK; Ayad NG; Lee JK
    Exp Neurol; 2018 Nov; 309():181-192. PubMed ID: 30134146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual-target inhibitors of bromodomain and extra-terminal proteins in cancer: A review from medicinal chemistry perspectives.
    Feng L; Wang G; Chen Y; He G; Liu B; Liu J; Chiang CM; Ouyang L
    Med Res Rev; 2022 Mar; 42(2):710-743. PubMed ID: 34633088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.